Oxigene Access

On June 20, 2016, OXiGENE officially became Mateon Therapeutics (formerly NASDAQ: OXGN, now MATN).

A second-generation VDA focused on hematologic malignancies; initiated Phase 1b/2 trials in 2015. Myopic Macular Degeneration

Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) Oxigene

In 2010, OXiGENE acquired VaxGen, Inc. in a stock-for-stock merger to bolster its cash reserves by approximately $33 million.

In 2009, OXiGENE re-acquired full rights to its lead candidates, ZYBRESTAT and OXi4503, from Symphony ViDA. Lead Pharmaceutical Pipeline On June 20, 2016, OXiGENE officially became Mateon

Unlike traditional anti-angiogenic drugs that prevent new vessel formation, OXiGENE’s VDAs targeted existing immature blood vessels within tumors. These agents compromise the tumor's core vasculature, leading to extensive necrosis (cell death) within the center of the tumor.

OXiGENE’s primary development programs were based on , natural products originally derived from the African bush willow tree. Drug Candidate Indication Current Status/Highlights CA4P (Fosbretabulin) Ovarian Cancer, Glioblastoma, Anaplastic Thyroid Cancer in a stock-for-stock merger to bolster its cash

Investigated as a topical or systemic treatment to prevent abnormal blood vessel leakage in the eye.